FDA, United Therapeutics

FDA approves first xenotransplantation clinical trial, as United Therapeutics forges ahead
United Therapeutics said the FDA has cleared it to begin the first clinical trial testing whether organs from gene-edited pigs could provide a viable option for human patients.
FDA Approves Transplant Trials for Gene-Edited Pig Kidneys
The FDA will allow two biotechnology companies to run clinical trials: United Therapeutics and eGenesis. United Therapeutics Corporation will start with six patients but could grow its trial to include up to 50 individuals, while eGenesis plans to begin with three patients.
FDA approves United Therapeutics' xeno-organ trial
Corporation (NASDAQ: UTHR) has received clearance from the U.S. Food and Drug Administration (FDA) to begin a pioneering clinical trial of its gene-edited xenotransplantation kidney, named UKidney, marking a milestone in potential treatment options for end-stage renal disease (ESRD) patients.
United Therapeutics scores FDA go-ahead for pig organ transplant clinical trial
Silver Spring’s United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to be transplanted into humans. It's as significant for the medical community as it is for the business.
United Therapeutics Says FDA Clears IND For The UKidney Xenotransplantation Clinical Trial
United Therapeutics Corp. (UTHR), a public benefit corporation, announced Monday that the U.S. Food and Drug Administration (FDA) has
FDA approves pig organ transplant trials for patients with kidney failure
The first clinical trials using organs from genetically modified pigs offer hope to patients with kidney failure, who face a long wait for human organ transplants.
US FDA greenlights clinical trails for pig kidney transplants in humans
The FDA has approved clinical trials for organ transplants using genetically modified pigs, starting with six patients with end-stage renal disease. If successful, the study may expand to 50 participants by mid-2025,
Experimental transplants with organs from gene-edited pigs see major steps forward
On Friday, doctors at Massachusetts General Hospital announced that a 66-year-old New Hampshire man had successfully received ...
New Hampshire man is 2nd person known to be living with a pig kidney
His effort paid off: Tim Andrews, 66, is only the second person known to be living with a pig kidney. Andrews is free from ...
United Therapeutics price target lowered to $460 from $475 at UBS
UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics ...
United Therapeutics president sells $3.5m in stock
Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock transactions, according to a recent SEC filing. On February 3, Benkowitz sold shares ...
United Therapeutics plans $96M facility for genetically edited swine in northeast Houston
United Therapeutics could eventually use the genetically edited swine to grow organs for human transplant recipients. A ...
Forbes9d
United Therapeutics
United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of unique products to address the unmet medical needs of patients with chronic ...
United Therapeutics: TETON 1 study of nebulized Tyvaso for IPF fully enrolled
United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...
Kingswood Wealth Advisors LLC Takes Position in United Therapeutics Co. (NASDAQ:UTHR)
Kingswood Wealth Advisors LLC bought a new position in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) during ...